Engineered immune cells take aim at Hard-to-Treat lupus

NCT ID NCT07659704

Not yet recruiting Disease control Sponsor: University of Sao Paulo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a one-time treatment called CAR-T cell therapy for people with systemic lupus erythematosus (lupus) that hasn't improved with standard medications. The therapy uses a patient's own immune cells, which are modified in a lab to find and destroy the B cells that drive lupus. The study will check if the treatment is safe and whether it can reduce disease activity and symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD19-directed CAR-T cells
What this could lead to: If it works, this could offer a new treatment option for people with severe lupus that doesn't respond to standard therapies, potentially leading to long-term disease control without ongoing medication.
What could go wrong: This is an early-phase trial with only 16 participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS ERYTHEMATOSUS, SYSTEMIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease lupus nephritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS ERYTHEMATOSUS, SYSTEMIC

Contacts and locations

Locations

Hospital das Clinicas de Ribeirão Preto (HCFMRP-USP)

Ribeirão Preto, São Paulo, 14048-900, Brazil
Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP)

São Paulo, São Paulo, 05403-010, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.